AU2022415459A1 - Manabodies targeting p53 tumor antigens and methods of using - Google Patents

Manabodies targeting p53 tumor antigens and methods of using Download PDF

Info

Publication number
AU2022415459A1
AU2022415459A1 AU2022415459A AU2022415459A AU2022415459A1 AU 2022415459 A1 AU2022415459 A1 AU 2022415459A1 AU 2022415459 A AU2022415459 A AU 2022415459A AU 2022415459 A AU2022415459 A AU 2022415459A AU 2022415459 A1 AU2022415459 A1 AU 2022415459A1
Authority
AU
Australia
Prior art keywords
seq
scfv
molecule
cancer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022415459A
Other languages
English (en)
Inventor
Sarah DINAPOLI
Sandra B. GABELLI
Emily Han-Chung HSIUE
Kenneth W. Kinzler
Brian J. MOG
Nickolas Papadopoulos
Bert Vogelstein
Katharine M. WRIGHT
Shibin Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2022415459A1 publication Critical patent/AU2022415459A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022415459A 2021-12-16 2022-12-15 Manabodies targeting p53 tumor antigens and methods of using Pending AU2022415459A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163290353P 2021-12-16 2021-12-16
US63/290,353 2021-12-16
PCT/US2022/053065 WO2023114430A1 (en) 2021-12-16 2022-12-15 Manabodies targeting p53 tumor antigens and methods of using

Publications (1)

Publication Number Publication Date
AU2022415459A1 true AU2022415459A1 (en) 2024-07-04

Family

ID=86773477

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022415459A Pending AU2022415459A1 (en) 2021-12-16 2022-12-15 Manabodies targeting p53 tumor antigens and methods of using

Country Status (10)

Country Link
US (1) US20250034252A1 (cg-RX-API-DMAC7.html)
EP (1) EP4448583A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024546923A (cg-RX-API-DMAC7.html)
KR (1) KR20240127981A (cg-RX-API-DMAC7.html)
CN (1) CN118541396A (cg-RX-API-DMAC7.html)
AU (1) AU2022415459A1 (cg-RX-API-DMAC7.html)
CA (1) CA3242393A1 (cg-RX-API-DMAC7.html)
IL (1) IL313491A (cg-RX-API-DMAC7.html)
MX (1) MX2024007456A (cg-RX-API-DMAC7.html)
WO (1) WO2023114430A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021127184A1 (en) 2019-12-17 2021-06-24 The Johns Hopkins University MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING
CN122438861A (zh) * 2023-11-13 2026-07-21 克拉斯普治疗有限公司 靶向肿瘤抗原并接合t细胞受体的修饰的mana-tce及其使用方法
WO2026088159A1 (en) * 2024-10-24 2026-04-30 Imuno Therapeutics Hla-a2 p53 antibodies and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6913032B2 (ja) * 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
GB201617564D0 (en) * 2016-10-17 2016-11-30 Agency For Science Technology And Research And National University Of Singapore And Singapore Health Anti-p53 antibodies
WO2021127184A1 (en) * 2019-12-17 2021-06-24 The Johns Hopkins University MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING

Also Published As

Publication number Publication date
EP4448583A4 (en) 2025-12-17
WO2023114430A1 (en) 2023-06-22
US20250034252A1 (en) 2025-01-30
JP2024546923A (ja) 2024-12-26
KR20240127981A (ko) 2024-08-23
CA3242393A1 (en) 2023-06-22
CN118541396A (zh) 2024-08-23
MX2024007456A (es) 2024-09-10
IL313491A (en) 2024-08-01
EP4448583A1 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
US20250034252A1 (en) Manabodies targeting p53 tumor antigens and methods of using
JP2023002706A (ja) 抗pdl1抗体、活性化可能抗pdl1抗体、およびその使用方法
US11155596B2 (en) Polypeptide
JP7381345B2 (ja) Manaボディおよび使用方法
EP2646469B1 (en) Chimeric rabbit/human ror1 antibodies
US20230190796A1 (en) Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
EP3368557B1 (en) New polypeptide
CA3266915A1 (en) MEDICAL USE OF ANTI-CCR8 ANTIBODIES AND DOSING PROGRAM
WO2023066389A1 (zh) 靶向pd-1的双特异性抗体、及其制备和应用
KR102887692B1 (ko) 항-bcam 항체 또는 그의 항원 결합 단편
US20250122303A1 (en) Treatment and prevention of cancer using her3 antigen-binding molecules
WO2018232164A1 (en) Antibody drug conjugates that bind lgr5
JP7813235B2 (ja) NPM1c陽性がんの免疫療法のための組成物および方法
KR20240058149A (ko) Vista 항원-결합 분자를 사용한 암의 치료 및 예방
CN115368457A (zh) 抗tigit抗体及其用途
JP2018529716A (ja) 癌幹細胞を阻害する組成物及び方法
CA3156540A1 (en) Humanized anti-ca ix antibodies and methods of their use
JP2024529467A (ja) Ct45に特異的に結合する抗原結合タンパク質
BR112018007154B1 (pt) Polipeptídeo de ligação a pd-l1, proteína de fusão, conjugado, complexo, composição compreendendo um polipeptídeo de ligação a pdl1, composição compreendendo uma proteína de fusão, composição compreendendo um conjugado e composição compreendendo um complexo
HK1255250B (en) New polypeptide having affinity to pd-l1
NZ741586B2 (en) New polypeptide having affinity to pd-l1